唑来膦酸联合硫酸吗啡缓释片治疗多发骨转移性疼痛的疗效及耐受性观察

Zoledronic Acid Plus Morphine Sulfate Sustained-release Tablet for Patients with Multiple Osseous Metastasis Pain

目的:探讨唑来膦酸联合硫酸吗啡缓释治疗多发骨转移性疼痛的疗效及耐受性。方法:选择恶性肿瘤伴多发性骨转移、初始为重度疼痛、经硫酸吗啡缓释片治疗14天以上疼痛未达到中度以上缓解者。共入组患者52例,给予唑来膦酸联合硫酸吗啡缓释片治疗,比较联合治疗前后疗效及不良反应。结果:联合治疗前疼痛评分为7.3,联合治疗后降至1.4(P<0.001),联合治疗总有效率76.9%,生活质量良好者比例由9.6%增至71.2%(P<0.001)。8例出现发热,对症处理后体温当日降至正常。结论:唑来膦酸联合硫酸吗啡缓释片治疗多发骨转移性顽固性疼痛,明显提高患者生活质量,副反应未见增加,疗效及耐受性好。

Objective： To evaluate the adverse effects of Zoledronic Acid combined with morphine sulfate Sustained-release tablet for the management of patients with multiple osseous metastasis pain. Methods： 52 cases were enrolled. They all had severe pain and didn＇t get midrange relief 14 days after treatment by morphine sulfate Sustained-release tablet.The effects after combined with Zoledronic Acid were observed. Results： The NRS decreased from 7.3 down to 1.4（P〈0.001）. Total effective rate was 76.9%. Quality of life was improved significantly（P〈0.001）. Fever happened in 8 cases and soon recovered. Conclusion： Zoledronic Acid combined with morphine sulfate Sustained-release tablet for the patients with multiple osseous metastasis pain is effective safe.